Roche Holding AG
Investor-Grade Deep Dive Research Report | March 2026

Forward-Looking Disclaimer: This report contains forward-looking statements based on current expectations and available data as of March 2026. Actual results may differ materially due to risks outlined in the Risks section.

Executive Summary

Roche Holding AG is one of the world's largest pharmaceutical and diagnostics companies, headquartered in Basel, Switzerland, founded in 1896 by Fritz Hoffmann-La Roche. As of 2025, Roche employs approximately 100,000 employees globally across over 100 countries.

CHF 61.5B FY 2025 Revenue +7% CER
35.5% EBITDA Margin Core OP CHF 21.8B
CHF 13.8B Net Income (IFRS) +58% CER
~100,000 Employees 100+ Countries
Revenue Mix by Segment (FY 2025)
CHF 61.5B Total Revenue
Pharma CHF 47.7B (77.6%) Diagnostics CHF 13.8B (22.4%)
Revenue Growth Trajectory (CHF Billions)
50 55 60 65 2021 2022 2023 2024 2025 62.8 63.3 58.7 58.3 61.5

Strategic Position

Roche is the global leader in oncology therapeutics and in vitro diagnostics. The company operates through two divisions: Roche Pharmaceuticals (CEO: Teresa Graham) focused on oncology, immunology, neuroscience, ophthalmology, and infectious diseases; and Roche Diagnostics (CEO: Matt Sause), the world's largest diagnostics company.

FY 2026 Guidance

MetricGuidance
Group Sales GrowthMid-single digits (4-6%) at CER
Core EPS GrowthHigh-single digits (7-9%) at CER
Expected LOE Impact~CHF 1.0 billion

Key Financial Metrics (FY 2025)

MetricValueYoY Change
Group SalesCHF 61.5 billion (~$69B)+7% CER
Pharmaceuticals SalesCHF 47.7 billion+9% CER
Diagnostics SalesCHF 13.8 billion+2% CER
Core Operating ProfitCHF 21.8 billion+13%
IFRS Net IncomeCHF 13.8 billion+58% CER
Core EPS—+11%
Dividend per ShareCHF 9.80+1.04% (39th increase)

Leadership / C-Suite

NameTitleSinceBackground
Dr. Thomas SchineckerCEO, Roche GroupMarch 2023Austrian. Former CEO of Roche Diagnostics. PhD in molecular biology.
Dr. Alan HippeCFO2011German/Swiss. PhD in business (summa cum laude). Former CFO of Continental AG.
Teresa GrahamCEO, Roche PharmaceuticalsMarch 2023American. Born 1973. BBA from George Washington University. Joined Genentech 2005.
Matt SauseCEO, Roche DiagnosticsJanuary 2023American. Born 1977. BA Microbiology, MBA (UC San Diego). Joined Roche 2002.
Severin SchwanChairman of the BoardMarch 2023Austrian/German/Swiss. Former CEO (2008-2023). Longest-serving major pharma CEO.

Top Growth Drivers - Pharmaceuticals

The five key growth drivers generated CHF 21.4 billion in 2025, up CHF 3.2 billion CER from 2024, successfully offsetting biosimilar erosion of legacy products.

ProductIndicationFY 2025 RevenueGrowthPatent Status
OcrevusMultiple sclerosis~CHF 7.0B (est.)+4-6%US: 2028-2029
VabysmoWet AMD, DMECHF 4.1B+12%~2035
XolairAsthma, food allergiesCHF 3.0B+32%Biosimilar era
HemlibraHemophilia ACHF 2.7B+6-11%~2031-2035
PhesgoHER2+ breast cancerCHF 2.4B+48%~2034-2035

R&D Pipeline Highlights

DrugIndicationPhaseExpected Readout
FenebrutinibRelapsing MS, PPMSPhase 3 ✓2026 filing
TrontinemabEarly Alzheimer'sPhase 32027-2028
CT-388/CT-996Obesity (GLP-1)Phase 2/32026-2027
RVT-3101Ulcerative colitis, Crohn'sPhase 3 planned2026-2027
ZilebesiranHypertension (siRNA)Phase 3Ongoing
GiredestrantHR+/HER2- breast cancerPhase 32026

Patent/Exclusivity Summary

ProductIndicationUS ExclusivityEU ExclusivityKey Risk
OcrevusMSOct 2028-20292028Biosimilar competition
HemlibraHemophilia A2031-20352031+Gene therapy
VabysmoAMD, DME~2035~2035Low near-term
TecentriqMultiple cancers~2030~2030I-O competition
KadcylaHER2+ breast2026-2027ExpiredADC biosimilars
PerjetaHER2+ breastQ2 2024 (expired)2023 (expired)Biosimilar approved

Ada Patient Finder - Top Candidates

Assessment based on: (a) diagnostic delay exists, (b) per-patient revenue exceeds $50K/year, (c) condition has >20% underdiagnosis.

RankDrugIndicationFit ScoreAddressable PatientsNet Rev/Patient
1EvrysdiSMA9/105,000-10,000$70K-240K
2OcrevusMS8/10300,000-400,000$47K-55K
3AlecensaALK+ NSCLC8/1010,000-15,000$100K-120K
4VabysmoAMD/DME7/103M-5M$9K-15K
5XolairCSU/Food Allergies7/10500K-1M$18K-27K
6HemlibraHemophilia A6/1010,000-15,000 (LMICs)$300K-420K

Ocrevus - Patient Finder Pitch Hook

"Multiple sclerosis patients experience an average 4-7 year diagnostic delay, with 54% initially misdiagnosed with conditions like migraine, anxiety, or fibromyalgia. Ada's AI-powered symptom assessment can identify MS red flags earlier, accelerating diagnosis for the estimated 500,000+ undiagnosed patients worldwide who could benefit from Ocrevus treatment."

Vabysmo - Patient Finder Pitch Hook

"Wet AMD patients lose an average of 15% of visual acuity before diagnosis due to delays averaging 1-3 years. For diabetic macular edema, over 50% of cases go undiagnosed despite regular diabetes care. Ada's symptom assessment can identify macular warning signs and drive urgent ophthalmology referrals, accelerating diagnosis for millions of patients who could preserve vision with Vabysmo."

Peer Comparison (FY 2025)

CompanyRevenueGrowthP/EDividend Yield
Roche$69B+7%25x3.7%
Merck & Co.$64B+8%18x2.4%
Pfizer$64B+2%12x5.8%
AbbVie$56B+4%15x3.9%
Novartis$50B+12%16x3.4%

Risks and Challenges

Risk CategoryDescriptionImpact
Patent CliffOcrevus (2028-29), Kadcyla (2026-27), Tecentriq (~2030)CHF 10B+ at risk
CompetitionKeytruda dominance; late obesity entry; Alzheimer's crowdedHigh
Pipeline RiskTecentriq NSCLC failure; tiragolumab mixed resultsMedium
Regulatory/PricingIRA Medicare negotiation; China VBP; EU reference pricingMedium
FX ExposureCHF strength (7% CER vs 2% CHF growth gap)Medium

Valuation Context

MetricValue (March 2026)
Market Cap~$341-368 billion
Enterprise Value~$345 billion
P/E Ratio24-26x
Dividend Yield3.7%
Price/Sales~3.8x

References

  1. Roche Annual Report 2025 - roche.com/investors/annualreport25
  2. Roche Investor Relations - FY 2025 Results (January 29, 2026)
  3. Roche Media Release - "Strong 2025 Results" - roche.com
  4. Roche Finance Report 2025 - PDF
  5. Roche Corporate History - roche.com/about/history
  6. FierceBiotech - Roche/Genentech Acquisition (2009)
  7. Chugai Pharmaceutical - Roche Alliance Overview
  8. Roche Leadership Biographies - roche.com/about/leadership
  9. DrugPatentWatch - Ocrevus Patent Analysis
  10. National MS Society - Diagnostic Journey Statistics
  11. World Federation of Hemophilia - Global Survey 2023
  12. PMC - Chronic Urticaria Diagnostic Delay Study (PMC8163939)
  13. ASCO - HER2+ Breast Cancer Treatment Gap Analysis (2024)
  14. Roche Media Release - Fenebrutinib Phase 3 Results (March 2026)
  15. Alnylam Investor Relations - Zilebesiran Phase 3
  16. ycharts.com - Roche Market Capitalization Data
  17. Coherent Market Insights - Various Drug Market Reports
  18. FiercePharma - Patent Expiration Analysis
  19. Roche Investor Update - 2026 Guidance
  20. Foundation Medicine Partnership Overview
  21. GoodRx - Ocrevus Pricing Data
  22. Medical News Today - Hemlibra Cost Analysis
  23. Roche JPMorgan Healthcare Conference Presentation (2025-2026)
  24. MarketScreener - Executive Committee Changes
  25. Pharmaceutical Technology - Revenue Analysis
  26. ResearchAndMarkets - Tecentriq Market Report
  27. Grand View Research - Various Drug Market Forecasts
  28. Roche Diagnostics Annual Performance Data
  29. StockAnalysis - Roche Dividend History
  30. Proclinical - Patent Expiration Timeline
  31. AMD Alliance International - Patient Journey Research
  32. SMA News Today - Diagnostic Delay Statistics
  33. PubMed - ALK+ NSCLC Diagnostic Pathway Analysis
  34. Hemophilia News Today - Prevalence Data
  35. Roche Media Release - Trontinemab Phase 3 Initiation
  36. Roche Media Release - Carmot Therapeutics Acquisition
  37. Clinical Trials Arena - Fenebrutinib Data
  38. European Round Table - Severin Schwan Profile
  39. BioSpace - Leadership Appointments
  40. iPharmacenter - Top Pharmaceutical Companies (2025)
  41. Drug Discovery Trends - Pharma 50 Rankings
  42. Investing.com - Roche Earnings Transcripts
  43. Trading Economics - Market Capitalization Data
  44. Roche Governance Documents - Board Composition
  45. BioPharma Dive - Industry Analysis
  46. Statista - Roche Diagnostics Sales by Segment
  47. MSIF - DMT Patent Overview (2022)